ClinicalTrials.gov
ClinicalTrials.gov Menu

A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01684475
Recruitment Status : Unknown
Verified September 2012 by Craig Hudson MD, Alexandra Marine and General Hospital.
Recruitment status was:  Recruiting
First Posted : September 13, 2012
Last Update Posted : September 13, 2012
Sponsor:
Information provided by (Responsible Party):
Craig Hudson MD, Alexandra Marine and General Hospital

September 11, 2012
September 13, 2012
September 13, 2012
September 2012
September 2013   (Final data collection date for primary outcome measure)
Reduced signs and symptoms of Parkinson's disease [ Time Frame: 8 weeks ]
Reduced signs and symptoms of Parkinson's disease
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE
A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE
The purpose of this study is to assess the ability of CJH1 to increase the sensitivity of dopamine receptors and thereby reduce symptoms of Parkinson's Disease.
Not Provided
Interventional
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Parkinson's Disease
Drug: CJH1 (CLR4001)
Experimental: Treatment with CJH1
Intervention: Drug: CJH1 (CLR4001)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
21
Same as current
September 2013
September 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient's with Parkinson's disease

Exclusion Criteria:

  • Contraindications to study medication
Sexes Eligible for Study: All
40 Years to 85 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
 
NCT01684475
CJH1 Trial
No
Not Provided
Not Provided
Craig Hudson MD, Alexandra Marine and General Hospital
Alexandra Marine and General Hospital
Not Provided
Not Provided
Alexandra Marine and General Hospital
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP